https://pharmadog.xyz/news/435551 pharmadog en 2026-09-21T14:45:54.000Z Iambic Therapeutics launches next-gen Enchant AI model and inks R&D partnership with AbbVie https://pharmadog.xyz/news/435575 pharmadog en 2026-09-21T14:36:41.000Z Novo outlines $23 billion 2035 revenue target, but investors react with a 7% share drop https://pharmadog.xyz/news/134233 pharmadog en 2026-09-21T14:11:00.000Z CLINUVEL to cut up to 20% of staff and move headquarters to New York https://pharmadog.xyz/news/435383 pharmadog en 2026-09-21T13:52:07.000Z Telix to acquire German radioisotope maker ITM in deal valued up to $2.35 billion https://pharmadog.xyz/news/435384 pharmadog en 2026-09-21T13:51:29.000Z ADARx aims for $318 million IPO as TRexBio and Retension also file https://pharmadog.xyz/news/435427 pharmadog en 2026-09-21T13:31:07.000Z Novo Nordisk vows to launch five multi-blockbuster drugs by 2030 as it shifts toward consumer-style products https://pharmadog.xyz/news/435407 pharmadog en 2026-09-21T13:13:52.000Z Telix to acquire ITM Isotope Technologies for $1.65 billion, adding late-stage radiopharma asset ITM-11 https://pharmadog.xyz/news/435634 pharmadog en 2026-09-21T12:58:34.000Z FDA issues rule to allow non-animal testing methods for drug safety https://pharmadog.xyz/news/435239 pharmadog en 2026-09-21T12:11:12.000Z Novo acquires three early-stage obesity assets from Kallyope to broaden pipeline amid investor pressure https://pharmadog.xyz/news/435259 pharmadog en 2026-09-21T12:03:49.000Z Trump calls for new vaccine while echoing vaccine misinformation https://pharmadog.xyz/news/435279 pharmadog en 2026-09-21T11:49:00.000Z Telix to acquire Germany's ITM for $1.65 billion, aiming to dominate radiopharmaceutical market https://pharmadog.xyz/news/435111 pharmadog en 2026-09-21T11:30:00.000Z Compass eyes J&J’s Spravato playbook for upcoming psychedelic drug COMP360 launch https://pharmadog.xyz/news/434923 pharmadog en 2026-09-21T11:00:00.000Z Alkermes' orexin agonist ALKS 7290 shows promise in early-stage ADHD trial https://pharmadog.xyz/news/434879 pharmadog en 2026-09-21T10:57:33.000Z Novo outlines diversification strategy with new pipeline assets and bolt-on deals https://pharmadog.xyz/news/435526 pharmadog en 2026-09-21T10:39:00.000Z White House considers executive order to politicize NIH grant approvals https://pharmadog.xyz/news/435527 pharmadog en 2026-09-21T10:27:00.000Z Novo Nordisk faces investor skepticism at Capital Markets Day as it outlines consumer and obesity growth plans https://pharmadog.xyz/news/434771 pharmadog en 2026-09-21T10:17:43.000Z Cue Biopharma's chronic hives drug clears Phase 2 trial, first immunology data after cancer pivot https://pharmadog.xyz/news/434647 pharmadog en 2026-09-21T09:33:45.000Z Novo Nordisk outlines new obesity and consumer-focused strategy, targets five multi-blockbusters by 2030 https://pharmadog.xyz/news/435358 pharmadog en 2026-09-21T09:12:00.000Z China aims for 25% of global first-in-class drugs by 2030 under new five-year plan https://pharmadog.xyz/news/434668 pharmadog en 2026-09-21T09:00:00.000Z Walgreens Specialty Pharmacy highlights holistic support to boost oncology medication adherence https://pharmadog.xyz/news/434667 pharmadog en 2026-09-21T09:00:00.000Z Healthcare systems lag behind rapid expansion of GLP-1 therapies, raising care and trust challenges https://pharmadog.xyz/news/434480 pharmadog en 2026-09-21T08:30:00.000Z Republican Iowa governor candidate teams with RFK Jr. as poll lag persists https://pharmadog.xyz/news/434484 pharmadog en 2026-09-21T08:30:00.000Z Experts urge ClinicalTrials.gov to add pregnancy and lactation checkbox to aid trial enrollment https://pharmadog.xyz/news/434483 pharmadog en 2026-09-21T08:30:00.000Z Addiction clinics see rising cases of kratom and 7-OH withdrawal https://pharmadog.xyz/news/434482 pharmadog en 2026-09-21T08:30:00.000Z STAT launches trust-in-science reporter to explore public skepticism of modern medicine https://pharmadog.xyz/news/434481 pharmadog en 2026-09-21T08:30:00.000Z STAT launches first trust-in-science reporter to explore declining public confidence in health research https://pharmadog.xyz/news/434479 pharmadog en 2026-09-21T08:30:00.000Z New KRAS-targeting drug daraxonrasib approved for pancreatic cancer as experts call for $100 billion NIH budget https://pharmadog.xyz/news/434099 pharmadog en 2026-09-21T06:00:58.000Z Beacon Therapeutics reports successful gene-therapy trial for rare X-linked retinitis pigmentosa https://pharmadog.xyz/news/434578 pharmadog en 2026-09-21T05:19:00.000Z Telix to acquire ITM Isotope for $1.65 billion, targeting radioligand therapy market https://pharmadog.xyz/news/434580 pharmadog en 2026-09-21T04:33:00.000Z TRex Bio and Retension Pharma announce plans for IPOs, outlining biotech pipeline funding https://pharmadog.xyz/news/433679 pharmadog en 2026-09-21T04:05:00.000Z Experts see Replimune’s Tudriqev approval as a step toward broader use of localized cancer therapies https://pharmadog.xyz/news/433680 pharmadog en 2026-09-21T04:02:00.000Z FDA’s new CBER and CDER heads back adaptive framework for rare disease therapies https://pharmadog.xyz/news/433681 pharmadog en 2026-09-21T04:00:00.000Z Transposase-based cell line platform speeds development and raises protein yields for complex biologics https://pharmadog.xyz/news/434410 pharmadog en 2026-09-21T03:52:00.000Z Cue Biopharma's CUE-221 meets primary endpoint in phase 2 CSU trial, eyes phase 2b/3 https://pharmadog.xyz/news/432751 pharmadog en 2026-09-20T23:25:57.000Z Telix to acquire ITM Isotope Technologies in $1.65 billion radiopharma merger https://pharmadog.xyz/news/433906 pharmadog en 2026-09-20T13:55:00.000Z Beacon Therapeutics reports positive pivotal trial results for X-linked retinitis pigmentosa gene therapy